Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Davis Jennifer L.Ownership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Quaggin Susan EOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Rapp Edward JOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Alpern Robert JOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Austin Roxanne SOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Burnside William H.L.Ownership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Freyman Thomas COwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Hart Brett JOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Meyer Melody BOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Roberts Rebecca BOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
Filings by filing date
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Davis Jennifer L.Ownership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Quaggin Susan EOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Rapp Edward JOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Alpern Robert JOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Austin Roxanne SOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Burnside William H.L.Ownership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Freyman Thomas COwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Hart Brett JOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Meyer Melody BOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
-
May 03, 2024 (filed on May 07, 2024)Insider Name:Roberts Rebecca BOwnership Type:Direct OwnershipSecurities:Common Stock, $0.01 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,322Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1 N Waukegan Rd NORTH CHICAGO IL 60064 |
Tel: | 1-847-9352211 |
Website: | https://www.abbvie.com |
IR: | See website |
Key People | ||
Richard A. Gonzalez Chairman of the Board, Chief Executive Officer | Kevin K. Buckbee Senior Vice President, Controller | Robert A. Michael President, Chief Operating Officer |
Scott T. Reents Chief Financial Officer, Executive Vice President | Timothy J. Richmond Chief Human Resource Officer, Executive Vice President | Perry C. Siatis Executive Vice President, General Counsel, Company Secretary |
Nicholas J. Donoghoe Executive Vice President, Chief Business and Strategy Officer | Azita Saleki-Gerhardt Executive Vice President, Chief Operations Officer | Jeffrey R. Stewart Executive Vice President, Chief Commercial Officer | Thomas J. Hudson Senior Vice President, Chief Scientific Officer - Global Research |
Business Overview |
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers. |
Financial Overview |
For the three months ended 31 March 2024, AbbVie Inc revenues increased 1% to $12.31B. Net income applicable to common stockholders increased from $228M to $1.36B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Fair Value Adjustments on Other Assets decrease of 65% to $660M (expense), Interest Income increase from $99M to $207M (income). |
Employees: | 50,000 as of Mar 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $342,974M as of Mar 31, 2024 |
Annual revenue (TTM): | $54,403M as of Mar 31, 2024 |
EBITDA (TTM): | $24,771M as of Mar 31, 2024 |
Net annual income (TTM): | $5,950M as of Mar 31, 2024 |
Free cash flow (TTM): | $11,241M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $55,932M as of Mar 31, 2024 |
Shares outstanding: | 1,765,867,781 as of Apr 25, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |